Streptococcus Pneumoniae Serotype 11A Conjugate Vaccine
This is a specialized pneumococcal vaccine designed to protect against Streptococcus pneumoniae serotype 11a, a bacterial strain that can cause serious infections such as pneumonia, meningitis, and bloodstream infections. The vaccine uses CRM197 protein conjugation technology, similar to other licensed pneumococcal conjugate vaccines, to enhance immune response against the capsular polysaccharide antigen.
A pneumococcal conjugate vaccine targeting serotype 11a, designed to prevent infections caused by this specific bacterial strain.
Key facts at a glance
- RxNorm
- 2566292
- Generic
- Streptococcus Pneumoniae Serotype 11a Capsular Antigen Diphtheria Crm197 Protein Conjugate Vaccine
- Class
- unclassified
- Brands
- Prevnar 20, Capvaxive
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- prefilled syringe
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Prevention of invasive pneumococcal disease, pneumonia, and other infections caused by Streptococcus pneumoniae serotype 11a. This serotype is included among the pneumococcal strains monitored by health authorities as a cause of invasive disease.
The vaccine contains the capsular antigen from S. pneumoniae serotype 11a, which is chemically conjugated to the CRM197 protein—a nontoxic mutant of diphtheria toxin used as a carrier protein. This conjugation converts the T-cell independent polysaccharide antigen into a T-cell dependent antigen, enhancing antibody production and immunological memory, particularly in young children whose immune systems respond poorly to unconjugated polysaccharides.
As a serotype-specific vaccine, this product only provides protection against serotype 11a and would need to be combined with other serotype-specific vaccines for broad pneumococcal coverage. Clinical development and regulatory status should be verified with current prescribing information. Like other conjugate vaccines, it may be suitable for populations who respond poorly to polysaccharide vaccines alone.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 30, 2026. · Read our editorial policy